Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Alkermes plc.

NASDAQ: ALKS · Life Sciences · 7 alerts · CIK 1520262

Share price
$46.53Close, Nov 16
Market cap
$7.82B
Shares outstanding
168.04MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Alkermes plc. filings on SEC EDGAR ↗

7:04 AM ET 8-K
Court & Legal Update

Alkermes Court & Legal Update

Alkermes entered into a settlement and license agreement with Teva Pharmaceuticals to resolve a patent infringement lawsuit regarding LYBALVI. Under the agreement, Teva is granted a non-exclusive, royalty-free license to market its generic version of the drug in the U.S. starting in November 2039, or May 2040 if pediatric exclusivity is obtained.

Counterparty
Teva Pharmaceuticals, Inc.
7:18 PM ET Form 4
Insider Selling

Alkermes EVP, CLO, Alkermes, Inc. David Joseph Gaffin Sells $94K of Stock

David Joseph Gaffin, EVP, CLO, Alkermes, Inc., sold 2,035 shares of Alkermes plc. at $46.17 a share, worth $94K in total on Nov 3, 2026. Shares held after the trade: 219,353 (-0.9%).

Value
$94K
Shares
2,035
Price
$46.17
Role
EVP, CLO, Alkermes, Inc.
Holding change
-0.9%
Trade date
Nov 3, 2026
9:22 AM ET 10-Q
Financial Results

Alkermes Q3 2026 Results: Net Income $16.3M, Down 80.3% YoY

Alkermes plc reported a significant increase in cash and cash equivalents to $631.3 million as of September 30, 2026, compared to $388.6 million at year-end 2025. The company's intangible assets grew substantially from $0.8 million to over $1.74 billion, reflecting the impact of the Avadel Acquisition and its expanded neuroscience portfolio including LUMRYZ.

Key figure
Net income $16.3M · -80.3% YoY
8:10 AM ET 8-K
Financial Results

Alkermes Financial Results

Alkermes plc reported third quarter 2026 total revenues of $480.1 million, driven by solid performance in its proprietary product portfolio including VIVITROL and LUMRYZ. The company reported GAAP net income of $16.3 million and reaffirmed its full-year 2026 financial expectations while highlighting progress in its orexin development programs.

Term
3 months

“We delivered solid commercial and financial performance in the third quarter while continuing to advance our portfolio of orexin 2 receptor agonists in central disorders of hypersomnolence and other neuropsychiatric conditions.”

Blair Jackson, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.